Advani S H, Mehta A R, Rao M R, Fakih A R, Sanghvi V D, Nair C N, Gopal R
Oncology. 1981;38(6):329-33. doi: 10.1159/000225582.
200 mg/m2 methotrexate given intravenously in a running drip for 6 h has been used as an initial adjuvant therapy in 38 patients with advanced head and neck cancer. The response rate is as high as 80%, with 21% achieving complete remission. Histologically, specimens were tumor free in 3 patients. Toxicity in 38 patients included leukopenia (4), mucositis (6) and diarrhea (1). This particular dose of methotrexate appears to be safe and usually does not need leucovorin rescue. Also, when given as initial treatment, it is effective in reduction of tumor bulk. A prolonged randomized trial is essential to determine its role in improving long-term survival.
200mg/m²甲氨蝶呤静脉滴注6小时，已被用作38例晚期头颈癌患者的初始辅助治疗。缓解率高达80%，21%达到完全缓解。组织学检查显示，3例患者的标本无肿瘤。38例患者的毒性反应包括白细胞减少（4例）、粘膜炎（6例）和腹泻（1例）。这种特定剂量的甲氨蝶呤似乎是安全的，通常不需要亚叶酸解救。此外，作为初始治疗时，它在缩小肿瘤体积方面有效。一项长期随机试验对于确定其在改善长期生存中的作用至关重要。
